Extracellular Vesicle-Derived mir-148a-3p Promotes Plasmablast Differentiation in Bullous Pemphigoid via BACH2 Repression and mTOR Activation
Listen to this summary
This study aims to elucidate the molecular mechanisms behind plasmablast differentiation in bullous pemphigoid (BP), an autoimmune blistering disease. The authors found that extracellular vesicle-derived miR-148a-3p enhances plasmablast differentiation by repressing BACH2 and activating the mTOR signaling pathway, suggesting a novel regulatory mechanism in BP pathogenesis and highlighting miR-148a-3p as a potential diagnostic and therapeutic target.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from The Journal of investigative dermatology
View all →More in Dermatology
View all →Aug 6, 2026 · Lancet (London, England)
[<sup>177</sup>Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial
Aug 5, 2026 · The New England journal of medicine
Syncope
Jul 31, 2026 · Lancet (London, England)
Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial
Jul 30, 2026 · Lancet (London, England)
Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
Jul 30, 2026 · Lancet (London, England)
Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
Jul 29, 2026 · Lancet (London, England)
Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
